Bioactivity | Bismuth potassium citrate (Bismuth tripotassium dicitrate) is an orally active gastric mucosal protector and has antibacterial and anti-inflammatory activity. Bismuth potassium citrate relieves stomach pain, resists H. pylori growth and repairs gastric mucosa. Bismuth potassium citrate combined with Omeprazole (HY-B0113) has a safe and high efficacy against H. pylori infection, which is promising for research of peptic ulcers, gastric cancer and tubulointerstitial nephritis[1][2][3][4][5][6]. |
In Vivo | Bismuth potassium citrate (50 mg/kg,口服,每日一次,14 天) 在大鼠胃中可以改善随着年龄增长而增加的对有害物质的易感性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
CAS | 57644-54-9 |
Formula | C12H10BiK3O14 |
Molar Mass | 704.47 |
Appearance | 固体 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. S M Hinsull, et al. Effect of colloidal bismuth subcitrate on age related gastric lesions in the rat. Gut. 1991 Apr;32(4):355-60. doi: 10.1136/gut.32.4.355. [2]. Luo HY, et al. Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects[J]. Drugs R D. 2024 Mar;24(1):81-87. [3]. JIANG J X. Efficacy of compound bismuth potassium citrate capsules combined with omeprazole in eradication of Helicobacter pylori infection: A clinical study[J]. Academic Journal of Second Military Medical University, 2010: 973-977. [4]. Mikhailova M, et al. BISMUT-INDUCED ONSET OF ACUTE TUBULOINTERSTICIAL NEPHRITIS: A CLINICAL CASE[J]. [5]. Naidenko E S, et al. Obtaining bismuth-potassium citrate[J]. Chemistry for Sustainable Development, 2012, 20: 523-528. [6]. Xuan Y, et al. High-security multifunctional nano-bismuth-sphere-cluster prepared from oral gastric drug for ct/pa dual-mode imaging and chemo-photothermal combined therapy in vivo[J]. Advanced Functional Materials, 2019, 29(18): 1900017. |